1. Home
  2. News
  3. Vectus Biosystems Limited
  4. Third S.A.D. Group Reviewed By Trial Safety Review Committee
More Vectus Biosystems Limited news
Vectus Biosystems LimitedASX: VBS

Third S.A.D. Group Reviewed By Trial Safety Review Committee

Nov 28, 2021 at 11:21 PM EST · Issued by Vectus Biosystems Limited

Filed with ASX · Nov 28, 2021 at 11:21 PM EST · 1 page · English

On 6ix: 6ix.com/news/third-sad-group-reviewed-by-trial-safety-review-committee

Vectus Biosystems Limited on 6ix

Earlier from Vectus Biosystems

  • Response to ASX Price and Volume QueryOct 19, 2021
  • Update on Phase I Human TrialSep 6, 2021
  • Successful Completion of First Group in Phase I Human TrialAug 23, 2021
  • Approval Received for Phase I Trial in AustraliaJun 16, 2021
  • Vectus completes $7 million placementNov 20, 2020

Later from Vectus Biosystems

  • Chairman & CEO Address to ShareholdersJan 24, 2022
  • A Significant Milestone for VB0004Feb 20, 2022
  • Half Yearly Report and Appendix 4DFeb 25, 2022
  • Completion of Final S.A.D. Study and First M.A.D. StudyMay 25, 2022
  • Quarterly Activities Report & Appendix 4CJul 28, 2022
All Vectus Biosystems news releases↗

Follow Vectus Biosystems into a list and get an email when it puts out news.

Follow Vectus Biosystems
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer